Patents by Inventor Richard Soll

Richard Soll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA Polymerase IIIC Inhibitors and Use Thereof
    Publication number: 20230250102
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 10, 2023
    Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20220356182
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 10, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Steven W. Ludmerer, Kun Liu, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • DNA Polymerase IIIC Inhibitors and Use Thereof
    Publication number: 20220112195
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.
    Type: Application
    Filed: April 2, 2021
    Publication date: April 14, 2022
    Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
  • DNA polymerase IIIC inhibitors and use thereof
    Patent number: 11001592
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 11, 2021
    Assignee: Acurx Pharmaceuticals, LLC
    Inventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
  • DNA polymerase IIIC inhibitors and use thereof
    Patent number: 10836772
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: November 17, 2020
    Assignee: Acurx Pharmaceuticals, LLC
    Inventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
  • DNA Polymerase IIIC Inhibitors and Use Thereof
    Publication number: 20200308180
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
  • DNA Polymerase IIIC Inhibitors and Use Thereof
    Publication number: 20200308179
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacterial infections.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20200262836
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: March 25, 2020
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: CRAIG A. COBURN, STEVEN W. LUDMERER, KUN LIU, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • Piperidine or piperazine linked imidazole and triazole derivatives and methods of use
    Patent number: 10745377
    Abstract: The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 18, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana M. Maletic, Yunfu Luo, Zhiqi Qi, Tingting Yu, Richard Soll
  • DNA polymerase IIIC inhibitors and use thereof
    Patent number: 10723741
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: July 28, 2020
    Assignee: Acurx Pharmaceuticals, LLC
    Inventors: Xiang Y. Yu, Li H. Xing, Minghua Wang, Casey McComas, Michael Silverman, Richard Soll
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20190127365
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 2, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Steven W. Ludmerer, Kun Liu, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
    Patent number: 9981969
    Abstract: The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana Maletic, Yunfu Luo, Zhiqi Qi, Chunsing Li, Tingting Yu, Richard Soll
  • Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 9573939
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: February 21, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD Italia SRL
    Inventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Qun Dang
  • Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
    Patent number: 9556202
    Abstract: The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: January 31, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana Maletic, Richard Soll, Chunsing Li, Yunfu Luo, Zhiqi Qi
  • Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
    Patent number: 9549921
    Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: January 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shuwen He, Zhong Lai, Xing Dai, Dong Xiao, Clare London, Nicolas Zorn, Ravi Nargund, Anandan Palani, Casey C. McComas, Peng Li, Xuanjia Peng, Richard Soll
  • Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
    Patent number: 9549917
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Casey C. McComas, Nigel J. Liverton, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Xing Dai, Hong Liu, Shuwen He, Zhong Lai, Qun Dang, Nicolas Zorn
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20170008906
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 12, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Steven W. Ludmerer, Kun Liu, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
    Patent number: 9504690
    Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: November 29, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Stuart B. Rosenblum, Joseph A. Kozlowski, Richard Soll, Hao Wu, Bin Hu, Bin Zhong, Dahai Wang, Changmao Shen, Fei Sun
  • PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
    Publication number: 20160297792
    Abstract: The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 13, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Craig A. Coburn, Milana M. Maletic, Yunfu Luo, Zhiqi Qi, Tingting Yu, Richard Soll
  • Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 9364482
    Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 14, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Ravi Nargund, Dong Xiao, Nicolas Zorn, Qun Dang, Casey C. McComas, Xuanjia Peng, Peng Li, Richard Soll